Brought to you by 
HaptoGuard gets rights to Oxis International's BXT-51072
01 Nov 2004
Executive Summary
HaptoGuard (focused on cardiovascular disease and inflammation) has licensed exclusive worldwide rights to develop, manufacture, and market Oxis International's (oxidative stress diseases) Phase II BXT-51072 for cardiovascular indications including acute coronary syndromes, atherosclerosis, and stroke.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
HaptoGuard gets rights to Oxis International's BXT-51072
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice